{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:08:39Z","timestamp":1792782519691,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"2025 Health Fellowship Foundation"},{"name":"Patient-Centered Clinical Research Coordinating Center","award":["RS-2025-02215225"],"award-info":[{"award-number":["RS-2025-02215225"]}],"id":[{"id":"https:\/\/ror.org\/00fzvsb30","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"DOI":"10.1007\/s00125-026-06870-8","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:39:25Z","timestamp":1790771965000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative hepatic effectiveness of empagliflozin vs dapagliflozin among individuals with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9364-3665","authenticated-orcid":false,"given":"Suyeon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5297-8826","authenticated-orcid":false,"given":"Hwa Yeon","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9668-2602","authenticated-orcid":false,"given":"Bin","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7253-6515","authenticated-orcid":false,"given":"Ju Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2622-6553","authenticated-orcid":false,"given":"Sungho","family":"Bea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1384-6123","authenticated-orcid":false,"given":"Jae Hyun","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2331-6126","authenticated-orcid":false,"given":"Young Min","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6945-9050","authenticated-orcid":false,"given":"Yoosoo","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6322-7753","authenticated-orcid":false,"given":"Christopher D.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-7525","authenticated-orcid":false,"given":"Ju-Young","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"issue":"1","key":"6870_CR1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev-pathol-121808-102132","volume":"5","author":"DG Tiniakos","year":"2010","unstructured":"Tiniakos DG, Vos MB, Brunt EM (2010) Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol Mech Dis 5(1):145\u2013171. https:\/\/doi.org\/10.1146\/annurev-pathol-121808-102132","journal-title":"Annu Rev Pathol Mech Dis"},{"issue":"10","key":"6870_CR2","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","volume":"22","author":"ZM Younossi","year":"2024","unstructured":"Younossi ZM, Golabi P, Price JK, et al (2024) The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes. Clin Gastroenterol Hepatol 22(10):1999-2010.e1998. https:\/\/doi.org\/10.1016\/j.cgh.2024.03.006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"6870_CR3","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"K Cusi","year":"2022","unstructured":"Cusi K, Isaacs S, Barb D et al (2022) American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract 28(5):528\u2013562. https:\/\/doi.org\/10.1016\/j.eprac.2022.03.010","journal-title":"Endocr Pract"},{"issue":"4","key":"6870_CR4","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/dom.13584","volume":"21","author":"K Cusi","year":"2019","unstructured":"Cusi K, Bril F, Barb D et al (2019) Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. Diabetes Obes Metab 21(4):812\u2013821. https:\/\/doi.org\/10.1111\/dom.13584","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"6870_CR5","doi-asserted-by":"publisher","first-page":"298","DOI":"10.2337\/dc19-0641","volume":"43","author":"S Kahl","year":"2020","unstructured":"Kahl S, Gancheva S, Stra\u00dfburger K et al (2020) Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial. Diabetes Care 43(2):298\u2013305. https:\/\/doi.org\/10.2337\/dc19-0641","journal-title":"Diabetes Care"},{"issue":"5","key":"6870_CR6","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2337\/dc18-1569","volume":"42","author":"A Latva-Rasku","year":"2019","unstructured":"Latva-Rasku A, Honka MJ, Kullberg J et al (2019) The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients. Diabetes Care 42(5):931\u2013937. https:\/\/doi.org\/10.2337\/dc18-1569","journal-title":"Diabetes Care"},{"issue":"2","key":"6870_CR7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s12072-024-10758-3","volume":"19","author":"M-T Weng","year":"2025","unstructured":"Weng M-T, Yang P-J, Liu P-F et al (2025) Effects of dapagliflozin on liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Hepatol Int 19(2):405\u2013414. https:\/\/doi.org\/10.1007\/s12072-024-10758-3","journal-title":"Hepatol Int"},{"issue":"Suppl 1","key":"6870_CR8","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.2337\/dc25-S004","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee (2024) 4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes\u20142025. Diabetes Care 48(Suppl 1):S59\u2013S85. https:\/\/doi.org\/10.2337\/dc25-S004","journal-title":"Diabetes Care"},{"issue":"8","key":"6870_CR9","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2337\/dc18-0165","volume":"41","author":"MS Kuchay","year":"2018","unstructured":"Kuchay MS, Krishan S, Mishra SK et al (2018) Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial). Diabetes Care 41(8):1801\u20131808. https:\/\/doi.org\/10.2337\/dc18-0165","journal-title":"Diabetes Care"},{"issue":"2","key":"6870_CR10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/dom.13520","volume":"21","author":"M Shimizu","year":"2019","unstructured":"Shimizu M, Suzuki K, Kato K et al (2019) Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab 21(2):285\u2013292. https:\/\/doi.org\/10.1111\/dom.13520","journal-title":"Diabetes Obes Metab"},{"key":"6870_CR11","doi-asserted-by":"publisher","first-page":"e083735","DOI":"10.1136\/bmj-2024-083735","volume":"389","author":"J Lin","year":"2025","unstructured":"Lin J, Huang Y, Xu B et al (2025) Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial. BMJ 389:e083735. https:\/\/doi.org\/10.1136\/bmj-2024-083735","journal-title":"BMJ"},{"issue":"3","key":"6870_CR12","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1053\/j.gastro.2021.10.051","volume":"162","author":"R Loomba","year":"2022","unstructured":"Loomba R, Ratziu V, Harrison SA (2022) Expert panel review to compare FDA and EMA guidance on drug development and endpoints in nonalcoholic steatohepatitis. Gastroenterology 162(3):680\u2013688. https:\/\/doi.org\/10.1053\/j.gastro.2021.10.051","journal-title":"Gastroenterology"},{"issue":"1","key":"6870_CR13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","volume":"14","author":"R Grempler","year":"2012","unstructured":"Grempler R, Thomas L, Eckhardt M et al (2012) Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 14(1):83\u201390. https:\/\/doi.org\/10.1111\/j.1463-1326.2011.01517.x","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"6870_CR14","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.rec.2024.01.011","volume":"77","author":"E S\u00e1nchez-Mu\u00f1oz","year":"2024","unstructured":"S\u00e1nchez-Mu\u00f1oz E, Requena-Ib\u00e1\u00f1ez JA, Badim\u00f3n JJ (2024) Dual SGLT1 and SGLT2 inhibition: more than the sum of its parts. Rev Esp Cardiol (Engl Ed) 77(7):510\u2013514. https:\/\/doi.org\/10.1016\/j.rec.2024.01.011","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"3","key":"6870_CR15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s40262-013-0126-x","volume":"53","author":"AJ Scheen","year":"2014","unstructured":"Scheen AJ (2014) Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet 53(3):213\u2013225. https:\/\/doi.org\/10.1007\/s40262-013-0126-x","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"6870_CR16","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.jclinepi.2014.12.016","volume":"68","author":"ME Flacco","year":"2015","unstructured":"Flacco ME, Manzoli L, Boccia S et al (2015) Head-to-head randomized trials are mostly industry sponsored and almost always favor the industry sponsor. J Clin Epidemiol 68(7):811\u2013820. https:\/\/doi.org\/10.1016\/j.jclinepi.2014.12.016","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"6870_CR17","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1093\/ije\/dyw253","volume":"46","author":"S CheolSeong","year":"2017","unstructured":"Cheol Seong S, Kim YY, Khang YH et al (2017) Data resource profile: the national health information database of the national health insurance service in South Korea. Int J Epidemiol 46(3):799\u2013800. https:\/\/doi.org\/10.1093\/ije\/dyw253","journal-title":"Int J Epidemiol"},{"issue":"12","key":"6870_CR18","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1001\/jama.2025.13350","volume":"334","author":"AG Cashin","year":"2025","unstructured":"Cashin AG, Hansford HJ, Hern\u00e1n MA et al (2025) Transparent reporting of observational studies emulating a target trial-the TARGET statement. Jama 334(12):1084\u20131093. https:\/\/doi.org\/10.1001\/jama.2025.13350","journal-title":"Jama"},{"issue":"8","key":"6870_CR19","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Robins JM (2016) Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol 183(8):758\u2013764. https:\/\/doi.org\/10.1093\/aje\/kwv254","journal-title":"Am J Epidemiol"},{"key":"6870_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-230x-6-33","volume":"6","author":"G Bedogni","year":"2006","unstructured":"Bedogni G, Bellentani S, Miglioli L et al (2006) The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 6:33. https:\/\/doi.org\/10.1186\/1471-230x-6-33","journal-title":"BMC Gastroenterol"},{"issue":"9","key":"6870_CR21","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.cgh.2012.12.031","volume":"11","author":"EM Koehler","year":"2013","unstructured":"Koehler EM, Schouten JN, Hansen BE,\u00a0Hofman A, Stricker BH, Janssen HL\u00a0(2013) External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. Clin Gastroenterol Hepatol 11(9):1201\u20131204. https:\/\/doi.org\/10.1016\/j.cgh.2012.12.031","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"6870_CR22","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","volume":"11","author":"K Yoshida","year":"2015","unstructured":"Yoshida K, Solomon DH, Kim SC (2015) Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol 11(7):437\u2013441. https:\/\/doi.org\/10.1038\/nrrheum.2015.30","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"6870_CR23","doi-asserted-by":"publisher","first-page":"e107584","DOI":"10.1371\/journal.pone.0107584","volume":"9","author":"YH Lee","year":"2014","unstructured":"Lee YH, Bang H, Park YM et al (2014) Non-laboratory-based self-assessment screening score for non-alcoholic fatty liver disease: development, validation and comparison with other scores. PLoS One 9(9):e107584. https:\/\/doi.org\/10.1371\/journal.pone.0107584","journal-title":"PLoS One"},{"issue":"38","key":"6870_CR24","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.2174\/1381612825666190117102111","volume":"24","author":"M Papatheodoridi","year":"2018","unstructured":"Papatheodoridi M, Cholongitas E (2018) Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): current concepts. Curr Pharm Des 24(38):4574\u20134586. https:\/\/doi.org\/10.2174\/1381612825666190117102111","journal-title":"Curr Pharm Des"},{"key":"6870_CR25","doi-asserted-by":"publisher","first-page":"l5657","DOI":"10.1136\/bmj.l5657","volume":"367","author":"RJ Desai","year":"2019","unstructured":"Desai RJ, Franklin JM (2019) Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. BMJ 367:l5657. https:\/\/doi.org\/10.1136\/bmj.l5657","journal-title":"Bmj"},{"issue":"7","key":"6870_CR26","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","volume":"42","author":"JH Lee","year":"2010","unstructured":"Lee JH, Kim D, Kim HJ et al (2010) Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 42(7):503\u2013508. https:\/\/doi.org\/10.1016\/j.dld.2009.08.002","journal-title":"Dig Liver Dis"},{"issue":"4","key":"6870_CR27","doi-asserted-by":"publisher","first-page":"845","DOI":"10.2307\/2530698","volume":"42","author":"DM Finkelstein","year":"1986","unstructured":"Finkelstein DM (1986) A proportional hazards model for interval-censored failure time data. Biometrics 42(4):845\u2013854","journal-title":"Biometrics"},{"issue":"1","key":"6870_CR28","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s12916-025-04017-x","volume":"23","author":"M Lee","year":"2025","unstructured":"Lee M, Hong S, Cho Y et al (2025) Synergistic benefit of thiazolidinedione and sodium-glucose cotransporter 2 inhibitor for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a 24-week, open-label, randomized controlled trial. BMC Med 23(1):266. https:\/\/doi.org\/10.1186\/s12916-025-04017-x","journal-title":"BMC Med"},{"issue":"6","key":"6870_CR29","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.2337\/dc25-0282","volume":"48","author":"A Mantovani","year":"2025","unstructured":"Mantovani A, Morandin R, Lando MG et al (2025) Sodium-glucose cotransporter 2 inhibitor use and risk of liver-related events in patients with type 2 diabetes: a meta-analysis of observational cohort studies. Diabetes Care 48(6):1042\u20131052. https:\/\/doi.org\/10.2337\/dc25-0282","journal-title":"Diabetes Care"},{"issue":"1","key":"6870_CR30","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1001\/jamainternmed.2024.6431","volume":"185","author":"GY Zhang","year":"2025","unstructured":"Zhang GY, Brandman D (2025) A clinical update on MASLD. JAMA Intern Med 185(1):105\u2013107. https:\/\/doi.org\/10.1001\/jamainternmed.2024.6431","journal-title":"JAMA Intern Med"},{"key":"6870_CR31","doi-asserted-by":"publisher","first-page":"109123","DOI":"10.1016\/j.diabres.2021.109123","volume":"182","author":"EJ Ku","year":"2021","unstructured":"Ku EJ, Lee DH, Jeon HJ, Oh TK (2021) Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study. Diabetes Res Clin Pract 182:109123. https:\/\/doi.org\/10.1016\/j.diabres.2021.109123","journal-title":"Diabetes Res Clin Pract"},{"key":"6870_CR32","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.diabres.2019.04.008","volume":"151","author":"EJ Ku","year":"2019","unstructured":"Ku EJ, Lee DH, Jeon HJ, Oh TK (2019) Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: a 52-week prospective observational study. Diabetes Res Clin Pract 151:65\u201373. https:\/\/doi.org\/10.1016\/j.diabres.2019.04.008","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"6870_CR33","first-page":"593","volume":"33","author":"M Hussain","year":"2021","unstructured":"Hussain M, Atif M, Babar M, Akhtar L (2021) Comparison of efficacy and safety profile of empagliflozin versus dapagliflozin as add on therapy in type 2 diabetic patients. J Ayub Med Coll Abbottabad 33(4):593\u2013597","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"6870_CR34","doi-asserted-by":"publisher","first-page":"155612","DOI":"10.1016\/j.metabol.2023.155612","volume":"145","author":"HJ Chun","year":"2023","unstructured":"Chun HJ, Kim ER, Lee M et al (2023) Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis. Metabolism 145:155612. https:\/\/doi.org\/10.1016\/j.metabol.2023.155612","journal-title":"Metabolism"},{"issue":"7","key":"6870_CR35","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMra2412865","volume":"393","author":"G Targher","year":"2025","unstructured":"Targher G, Valenti L, Byrne CD (2025) Metabolic dysfunction-associated steatotic liver disease. N Engl J Med 393(7):683\u2013698. https:\/\/doi.org\/10.1056\/NEJMra2412865","journal-title":"N Engl J Med"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-026-06870-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-026-06870-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-026-06870-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:39:26Z","timestamp":1790771966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-026-06870-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":35,"alternative-id":["6870"],"URL":"https:\/\/doi.org\/10.1007\/s00125-026-06870-8","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"28 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Part of this work was previously presented as an abstract at the ACPE annual meeting in 2025.","order":1,"name":"Ethics","label":"Acknowledgements","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The data supporting the findings of this study are available from the NHIS of South Korea. However, due to domestic privacy laws and regulations prohibiting the public release of individual data, these data are not publicly accessible. They can be obtained from the authors upon reasonable request, subject to approval from the NHIS.","order":2,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study was conducted with the support of the 2025 Health Fellowship Foundation. This research was supported by a grant from the Patient-Centered Clinical Research Coordinating Center (PACEN) funded by the Ministry of Health & Welfare, Republic of Korea (grant number: RS-2025-02215225). CDB is funded in part by the Southampton National Institute for Health and Care Research, Biomedical Research Centre (NIHR203319). The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.","order":3,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"JYS received grants from the Ministry of Food and Drug Safety, the National Research Foundation of Korea, Pfizer, Johnson & Johnson and GSK. CDB has received research funding from Echosens. The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work.","order":4,"name":"Ethics","label":"Authors\u2019 relationships and activities","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"SK and HYK were responsible for study concept and design, analysis and interpretation of data, drafting of the manuscript and critical revision of the manuscript. BH, JHK, SB, JHB, YMC, YC and CDB were responsible for study concept and design, interpretation of data and critical revision of the manuscript. JYS was responsible for study concept and design, interpretation of data, technical or material support, critical revision of the manuscript and study supervision. JYS had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. JYS is the guarantor. All authors read and approved the final manuscript.","order":5,"name":"Ethics","label":"Contribution statement","group":{"name":"EthicsHeading","label":"Ethics"}}]}}